These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19319016)

  • 1. Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of 7-valent pneumococcal conjugate vaccine: lack of association between Kawasaki disease and seven-valent pneumococcal conjugate vaccine.
    Center KJ; Hansen JR; Lewis E; Fireman BH; Hilton B
    Pediatr Infect Dis J; 2009 May; 28(5):438-40. PubMed ID: 19319016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany.
    Kieninger DM; Kueper K; Steul K; Juergens C; Ahlers N; Baker S; Jansen KU; Devlin C; Gruber WC; Emini EA; Scott DA;
    Vaccine; 2010 Jun; 28(25):4192-203. PubMed ID: 20417262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.
    Reinert P; Benkerrou M; de Montalembert M; Lesprit E; Abadie I; Bernaudin F; Doit C; Bingen E; Tetelboum R; Bonnet E
    Pediatr Infect Dis J; 2007 Dec; 26(12):1105-9. PubMed ID: 18043446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: a prospective study of safety and immunogenicity.
    Barton M; Wasfy S; Dipchand AI; Hébert D; Ng V; Solomon M; Fecteau A; Stephen D; Allen U
    Pediatr Infect Dis J; 2009 Aug; 28(8):688-92. PubMed ID: 19633514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.
    Millar EV; Watt JP; Bronsdon MA; Dallas J; Reid R; Santosham M; O'Brien KL
    Clin Infect Dis; 2008 Oct; 47(8):989-96. PubMed ID: 18781875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children.
    Tseng HF; Sy LS; Liu IL; Qian L; Marcy SM; Weintraub E; Yih K; Baxter R; Glanz JM; Donahue J; Naleway A; Nordin J; Jacobsen SJ
    Vaccine; 2013 May; 31(22):2578-83. PubMed ID: 23579258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006).
    Oosterhuis-Kafeja F; Beutels P; Van Damme P
    Vaccine; 2007 Mar; 25(12):2194-212. PubMed ID: 17267077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with the 7-valent conjugate pneumococcal vaccine: impact evaluation, continuing surveillance and future perspectives.
    Bechini A; Boccalini S; Bonanni P
    Vaccine; 2009 May; 27(25-26):3285-90. PubMed ID: 19200829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations.
    Adam D; Fehnle K
    Vaccine; 2008 Nov; 26(47):5944-51. PubMed ID: 18801402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with pneumococcal conjugate vaccine in Norway.
    Aaberge IS
    Expert Rev Vaccines; 2009 Feb; 8(2):159-65. PubMed ID: 19196196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
    Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
    Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results.
    Baker MA; Baer B; Kulldorff M; Zichittella L; Reindel R; DeLuccia S; Lipowicz H; Freitas K; Jin R; Yih WK
    PLoS Med; 2019 Jul; 16(7):e1002844. PubMed ID: 31265459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM(197) protein conjugate; Prevenar ) in Korean infants: differences that are found in Asian children.
    Kim NH; Lee J; Lee SJ; Lee H; Kim KH; Park SE; Lee HJ
    Vaccine; 2007 Nov; 25(45):7858-65. PubMed ID: 17931753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Neuzil KM; Whitney CG; Starkovich P; Dunstan M; Yu O; Nelson JC; Feikin DR; Shay DK; Baggs J; Carste B; Nahm MH; Carlone G
    Vaccine; 2005 May; 23(28):3697-703. PubMed ID: 15882530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007.
    Ardanuy C; Tubau F; Pallares R; Calatayud L; Domínguez MA; Rolo D; Grau I; Martín R; Liñares J
    Clin Infect Dis; 2009 Jan; 48(1):57-64. PubMed ID: 19035779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation.
    Cordonnier C; Labopin M; Chesnel V; Ribaud P; De La Camara R; Martino R; Ullmann AJ; Parkkali T; Locasciulli A; Yakouben K; Pauksens K; Einsele H; Niederwieser D; Apperley J; Ljungman P;
    Clin Infect Dis; 2009 May; 48(10):1392-401. PubMed ID: 19368505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine.
    Dinleyici EC; Yargic ZA
    Expert Rev Vaccines; 2009 Aug; 8(8):977-86. PubMed ID: 19627181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
    Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
    Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.